Quarterly report pursuant to Section 13 or 15(d)

Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.19.3
Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Finite-lived Intangible Assets, Gross $ 50,920 $ 43,620
Finite-lived Intangible Assets, Accumulated Amortization (16,388) (13,767)
Finite-lived Intangible Assets, Net Carrying Value $ 34,532 $ 29,853
CLIA Lab [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days 2 years 3 months 19 days
Finite-lived Intangible Assets, Gross $ 609 $ 609
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years 9 years
Finite-lived Intangible Assets, Gross $ 8,519 $ 8,519
RedPath Acquisition [Member] | Pancreas Test [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 7 years 7 years
Finite-lived Intangible Assets, Gross $ 16,141 $ 16,141
RedPath Acquisition [Member] | Barrett's Test [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years 9 years
Finite-lived Intangible Assets, Gross $ 18,351 $ 18,351
BioPharma Acquisition [Member] | Trademarks [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 10 years 10 years
Finite-lived Intangible Assets, Gross $ 1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 8 years 8 years
Finite-lived Intangible Assets, Gross $ 5,700